Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - glycerol, quantity: 100 mg/g; white soft paraffin, quantity: 50 mg/g; light liquid paraffin, quantity: 100 mg/g - cream - excipient ingredients: cetomacrogol 1000; self-emulsifying glyceryl monostearate; stearic acid; squalane; cetostearyl alcohol; laureth-3; purified water; dimeticone 350; glyceryl monostearate; dichlorobenzyl alcohol; methyl hydroxybenzoate - treatment of dry skin, scaly skin, winter itch, icthyosis, xerosis, dermatitis and other dry dermatological conditions. for the relief of symptoms of atopic eczema and psoriasis.

Malta - English - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - dimeticone, aluminium oxide, hydrated, magnesium hydroxide - chewable tablet - dimeticone 25 milligram(s) ; aluminium oxide, hydrated 200 milligram(s) ; magnesium hydroxide 200 milligram(s) - drugs for acid related disorders

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - dimeticone 3%{relative}; glycerol 10%{relative};  ; light liquid paraffin 10%{relative};  ;  ; squalane 3%{relative}; white soft paraffin 5%{relative};  ; glycerol 10%{relative}; light liquid paraffin 10%{relative}; white soft paraffin 5%{relative} - topical cream - active: dimeticone 3%{relative} glycerol 10%{relative}   light liquid paraffin 10%{relative}     squalane 3%{relative} white soft paraffin 5%{relative}   excipient: glyceryl monostearate stearic acid active: glycerol 10%{relative} light liquid paraffin 10%{relative} white soft paraffin 5%{relative} excipient: cetomacrogol cetostearyl alcohol dichlorobenzyl alcohol dimeticone glyceryl monostearate lauromacrogol 150 methyl hydroxybenzoate purified water squalane stearic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - dimeticone, activated - capsules, soft - 240 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

ethicare pharmaceuticals pty ltd - liquid paraffin, quantity: 5 %; zinc oxide, quantity: 20 %; benzoin sumatra, quantity: 1.2 %; aluminium chlorohydrate, quantity: 2 %; dimeticone 350, quantity: 10 % - paste - excipient ingredients: ethanol; emulsifying wax; white soft paraffin - prevention and treatment of nappy rash

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 5.1 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; polyethylene terephthalate; polyvinylidene flouride; titanium dioxide; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - dimeticone 350 - cutaneous cream - 100mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; erythrosine; sucrose; pregelatinised starch; flavour - keflor is indicated for the treatment of the following types of infections caused by or likely to be caused susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflor appears to be effective as phenoxymethul penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organisms to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 26.22 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; erythrosine; sucrose; pregelatinised starch; flavour - keflor is indicated for the treatment of the following types of infections caused by or likely to be caused susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflor appears to be effective as phenoxymethul penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organisms to cefaclor.